Tetragon Partners GP Ltd
GRAND CAYMAN, null · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$757.5M2026 Q3+ $8.5M options (notional, not included)
Positions37
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.79.8%
What Changed This Quarter?
Top Holdings
PATH
UiPath
54.5%
KGEI
Kolibri Global Energy
5.5%
SLN
Silence Therapeutics
3.5%
PHVS
Pharvaris N.V.
3.5%
IONS
Ionis Pharmaceuticals
2.6%
AUTL
Autolus Therapeutics
2.4%
ARWR
Arrowhead Pharmaceuticals
2.3%
LYFT
Lyft
2.0%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.